NewAmsterdam Pharma Company N.V. (NAMS) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everybody. Thank you for joining us today for our annual investor day. I'm pleased to have Michael Davidson, our CEO, John Kastelein, our chief scientific officer, and BJ Jones, our chief commercial officer, here with us today speaking, along with many members of our team. Ian Somaiya will also be available for questions afterwards for the presentation. Before we get started, The fun part, we will be making forward-looking statements today. I would advise everyone to please read our forward-looking statement page either here in the room or also available online at this time. As we mentioned, today we'll have Michael going through a general corporate update and introduction. We'll have John presenting the science, then we'll go back to Michael for an update on Pervail, as well as some of the updates on AD, and then BJ will be going through commercial. At this time, I'd like to have Michael come up and join us. Michael. Thank you, Matt, and thanks, everyone, for being here. We're very excited to share with you our science and corporate update. For us, this is our third Investor Day Science Day, and for John and I, it's one of our favorite days of the year. We get a chance to talk to you about what we're doing at New Amsterdam, all our... Achievements, of course, for us, the most exciting thing about the company is developing new science, helping patients, and so we really want to share with you all our insights and where we are, and look forward to your comments and questions afterwards. So we have a new mission statement that I'd like to review with you. Our mission is to hold a new standard of care for people living with cardiometabolic disease by challenging Connections with courage, transferring deep biologic insights into meaningful patient impact in...